UltraTech Cement Limited (BOM:532538)

Revance Therapeutics Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	4,672	5,536	3,704	1,205	1,772
Short-Term Investments	-	10,368	3,877	6,228	3,985	19,327
Trading Asset Securities	-	28,091	51,348	58,166	46,283	105,939
Cash & Short-Term Investments	43,130	43,130	60,761	68,098	51,473	127,037
Cash Growth	-31.19%	-29.02%	-10.77%	32.30%	-59.48%	175.61%
Accounts Receivable	-	58,903	42,782	38,670	30,716	25,717
Other Receivables	-	12,272	10,593	10,547	11,917	13,675
Receivables	-	71,302	53,667	49,438	42,701	39,445
Inventory	-	95,630	83,297	66,118	55,956	40,180
Prepaid Expenses	-	1,105	856.5	1,210	705.9	1,281
Restricted Cash	-	-	-	-	-	17
Other Current Assets	-	26,205	33,003	22,386	23,963	32,543
Total Current Assets	-	237,372	231,584	207,249	174,799	240,503
Property, Plant & Equipment	-	830,392	578,251	517,056	485,480	453,063
Long-Term Investments	-	29,095	27,644	14,609	14,107	12,868
Goodwill	-	76,818	63,455	63,293	62,502	62,199
Other Intangible Assets	-	100,774	55,182	55,846	54,740	55,721
Long-Term Deferred Tax Assets	-	650.9	49	65.6	163.5	71.6
Other Long-Term Assets	-	61,707	51,772	55,660	46,390	37,364
Total Assets	-	1,336,972	1,008,020	913,870	838,278	861,835
Accounts Payable	-	93,275	84,783	72,093	58,628	45,482
Accrued Expenses	-	32,282	28,053	26,549	24,146	7,492
Short-Term Debt	-	66,568	44,412	34,773	42,714	42,351
Current Portion of Long-Term Debt	-	5,934	5,494	10,671	6,284	27,042
Current Portion of Leases	-	2,030	1,625	1,463	1,178	1,126
Current Income Taxes Payable	-	19,896	19,835	13,664	5,273	7,117
Current Unearned Revenue	-	5,411	5,268	3,845	4,653	4,153
Other Current Liabilities	-	98,254	79,591	71,260	58,676	71,154
Total Current Liabilities	-	323,650	269,060	234,318	201,552	205,917
Long-Term Debt	-	157,808	53,078	53,564	53,030	135,485
Long-Term Leases	-	8,682	9,421	10,107	9,782	11,191
Long-Term Unearned Revenue	-	-	35	36.7	38.3	40
Long-Term Deferred Tax Liabilities	-	95,794	64,478	62,601	60,332	60,407
Other Long-Term Liabilities	-	12,104	9,115	6,757	6,315	6,297
Total Liabilities	-	598,038	405,186	370,068	333,956	420,031
Common Stock	-	2,947	2,887	2,887	2,887	2,887
Additional Paid-In Capital	-	113,110	54,874	54,844	54,771	54,697
Retained Earnings	-	588,641	542,493	483,710	443,785	378,983
Treasury Stock	-	-4,169	-3,417	-2,569	-1,543	-775
Comprehensive Income & Other	-	6,538	5,438	4,372	4,453	5,956
Total Common Equity	707,068	707,068	602,275	543,245	504,353	441,747
Minority Interest	-	31,866	559.4	556.3	-30.6	57.2
Shareholders' Equity	738,934	738,934	602,834	543,802	504,322	441,804
Total Liabilities & Equity	-	1,336,972	1,008,020	913,870	838,278	861,835
Total Debt	241,022	241,022	114,030	110,577	112,988	217,194
Net Cash (Debt)	-197,891	-197,891	-53,269	-42,480	-61,515	-90,157
Net Cash Per Share	-672.21	-672.19	-184.69	-147.25	-213.19	-312.44
Filing Date Shares Outstanding	294.16	294.15	288.19	288.27	288.4	288.46
Total Common Shares Outstanding	294.16	294.15	288.19	288.27	288.4	288.46
Working Capital	-	-86,278	-37,476	-27,069	-26,753	34,586
Book Value Per Share	2403.76	2403.76	2089.87	1884.53	1748.82	1531.39
Tangible Book Value	529,476	529,476	483,638	424,107	387,111	323,827
Tangible Book Value Per Share	1800.02	1800.02	1678.20	1471.24	1342.29	1122.60
Land	-	195,369	88,988	81,312	79,224	75,906
Buildings	-	91,011	66,046	61,841	57,343	55,160
Machinery	-	678,279	519,411	467,270	410,135	389,890
Construction In Progress	-	61,883	67,828	40,349	47,773	16,810

Source: S&P Global Market Intelligence. Standard template. Financial Sources.